Drug Profile
INT 1B3
Alternative Names: INT-1B3Latest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator InteRNA Technologies
- Class Antineoplastics; MicroRNAs
- Mechanism of Action Adenosine A2 receptor antagonists; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Liver cancer; Malignant melanoma
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 21 Feb 2024 Phase-I development for INT 1B3 is ongoing in Belgium (NCT04675996)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Belgium (IV, Infusion)
- 24 Mar 2023 InteRNA Technologies terminates phase-I clinical trials in Solid tumours ( (Late-stage disease, Metastatic disease)) in Belgium and Netherlands (NCT04675996)